A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114

Project: Other project

StatusActive
Effective start/end date2/8/172/7/20

Funding

  • Merck and Company: $6,615.38